1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in ...
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in ...
1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine ...
Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer First line treatment for patients with advanced, non-small cell lung cancers that ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.